# OnCo record vivacta-bio (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/vivacta-bio/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "vivacta-bio" ;
  schema:name "Vivacta Bio"@en ;
  schema:alternateName "Vivacta Biotechnology (Shanghai) Co., Ltd."@en, "IVACTA Biotechnology"@en, "Weitao Bio"@en ;
  schema:description "Vivacta Bio is a Shanghai company giving CAR-T therapy as an injection that reprogrammes a patient's T cells inside the body, instead of making the cells in a laboratory. Its first product, aimed at B-cell blood cancers and autoimmune disease, showed early human results at a December 2025 meeting."@en ;
  schema:url <https://onco.cc/companies/vivacta-bio/> ;
  schema:dateModified "2026-10-29"^^xsd:date ;
  schema:citation <https://www.prnewswire.com/news-releases/vivacta-bio-closed-series-a-and-series-a-financing-of-over-us50-million-302756983.html>, <https://www.vcbeathealth.com/article/2024>, <https://www.vcbeathealth.com/article/12193> ;
  schema:addressCountry "CN" ;
  onco:sections <https://onco.cc/fronts/cell-therapy/>, <https://onco.cc/fronts/immunotherapy/> ;
  onco:technologies <https://onco.cc/technologies/in-vivo-car-t/> ;
  onco:targets <https://onco.cc/targets/cd19/> ;
  onco:companies <https://onco.cc/companies/grit-bio/> .